Armed with $45 million in fresh capital, NewLimit says breakthroughs are bringing its age-reversal science closer to reality
NewLimit, a biotech company focused on reversing the aging process and co-founded by Brian Armstrong, the CEO of cryptocurrency exchange Coinbase, has raised an additional $45 million from a mix of new and existing investors, just five months after closing its $130 million Series B.
The round drew new investors, including Eli Lilly and Company, Duke Management Co. and Section 32, along with continued support from Abstract, Kleiner Perkins, Dimension, Human Capital and Boost. The new capital was raised at a $1.6 billion valuation cap.
NewLimit said the raise was “propelled by new technical breakthroughs” following its Series B that set the stage for its first clinical study in a few years. The biotech company says it’s developing medicines to restore youthful function in old cells through epigenetic reprogramming.
In the blog post announcing the new funding, NewLimit’s founders Armstrong, Jacob C. Kimmel, Blake Byers and head of operations Cathy O’Hare wrote that they are “firm believers” that a “new class of longevity medicines” can improve the lives of everyone on the planet, even those not diagnosed with “classically defined disease.”
The company says its lead programs have already shown “significant advances” since the Series B closed earlier this year, giving the team confidence to begin planning for clinical studies.
NewLimit’s July–August 2025 update shows a summer of real progress, including the launch of a vascular program focused on rejuvenating endothelial cells, which line the body’s veins and arteries, added several new hires across teams and welcomed Benjamin Humphreys and Matthew Breyer to its Scientific Advisory Board.
